Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Annals of Hematology

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia

Published in:
Authors
Francesca Morelli
Silvia Linari
Chiara Maria Rapolla
Monica Attanasio
Francesca Salvianti
Alessandro Sanna
Published in
Annals of Hematology | Issue 4/2026

Abstract

Venetoclax-obinutuzumab therapy successfully induced remission of acquired von Willebrand syndrome (AVWS) in a 72-year-old patient with chronic lymphocytic leukemia (CLL). Initially diagnosed with CLL, the patient later experienced severe bleeding due to AVWS, as evidenced by reduced factor VIII (FVIII) and von Willebrand factor (VWF) levels. Despite initial treatment with VWF/FVIII concentrates and tranexamic acid, persistent bleeding prompted the initiation of venetoclax-obinutuzumab. This regimen resulted in normalization of coagulation parameters and undetectable minimal residual disease, indicating effective CLL control and subsequent AVWS remission. This case highlights the potential of targeted CLL therapies in the management of rare associated hematologic complications.
Title
Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia
Authors
Francesca Morelli
Silvia Linari
Chiara Maria Rapolla
Monica Attanasio
Francesca Salvianti
Alessandro Sanna
Publication date
14-03-2026
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2026
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-026-06889-2
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 4/2026

The optimal conditioning intensity of stem cell transplantation for acute myeloid leukemia in complete remission

Elevated tricuspid regurgitation velocity in adults with sickle cell disease and HbAA controls in Kinshasa, Democratic Republic of the Congo: a comparative cross-sectional study

Lipegfilgrastim for primary prophylaxis of febrile neutropenia in patients treated for advanced-stage classical hodgkin lymphoma: successful outcomes from a multicenter cohort study

A Multi-Omics and machine learning platelet-related prognostic signature in multiple myeloma

Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more

Keynote webinar | Spotlight on progress in colorectal cancer

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Prof. Antoni Castells
Prof. Harpreet Wasan
Prof. Edward Giovannucci
Watch now
Video
Image Credits
Nurse checking IV drip bag/© Gorodenkoff / Stock.adobe.com (symbolic image with model), DNA double helix structure on a purple background/© 2025 Adobe, Colon cancer illustration/© (M) KATERYNA KON / SCIENCE PHOTO LIBRARY / Getty Images